Hoechst Aktiengesellschaft

The Scripps Research Institute

Aventis Pharma Deutschland, Gmbh

Beiersdorf Ag

Glycorex Ab

Wilhelm Stahl

Kyriacos Costa Nicolaou

Joachim Wink

Erwin Paul Schreiner

Laszlo Vertesy

Peter Emmanuel Maligres

Chan-Kou Hwang

Adrian Leonard Smith

Wei-Min Dai

Toshio Suzuki

Susanne Grabley

Axel Walch

Jozsef Aszodi

Gerhard Kretzschmar

Rudolf Schleyerbach

Astrid Markus

Dieter Isert

Michael Ahlers

Gunther J Riess

Martin Knauf

Dominique Le Beller

Sebastian V Wendeborn

Eckhart Bartnik

Anuschirwan Peyman

Michael Kurz

Herbert Kogler

Irvin Winkler

Gunther Schneider

Dieter Ruppert

Rainer Kropke

Karl-Heinz Budt

Bernd Kirschbaum

Matthias Wiesner

Wolfgang Pape

Sebastian V Wenderborn

Heike Stump

J&uuml;rgen Backhaus

Robert D Groneberg

Michael Meisterernst

Henning Schussler

Konrad Wagner

Antifungal peptides from scleroderma texense

An process for analyzing transcription which can be automated and which is suitable for bulk screening. The process involves transcribing a DNA sequence using a nuclear extract, which can be complemented or fully replaced by exogenous transcription factors and/or cofactors; optionally removing the proteins of the reaction mixture; binding the resulting transcript to a solid matrix; removing the excess labeled nucleotides; and determining the amount of labeled transcript. Methods of using the inventive process to identify compounds having a selective effect on gene expression.

In-vitro transcription processes for screening natural products and other chemical substances

Carbohydrate-containing polymers which can have an HLB* of from about 10 to about 20 are disclosed. The compounds comprise a hydrophilic polymer portion, a carbohydrate portion comprising from 1 to about 20 naturally occurring, identical or different, monosaccharide units, at least one bifunctional spacer coupling the carbohydrate portion to the hydrophilic polymer portion, and a potentiator moiety. The potentiator moiety can be is a crosslinking moiety located within the hydrophilic polymer or a hydrophobic, hydrophilic or ionic moiety. Processes for the preparation and use of such polymers are also disclosed.

Methods for preparing carbohydrate-containing hydrophilic polymers

This invention relates to the antibiotic feglymycin, as well as processes for its preparation and use. Feglymycin is represented by the structural formula (SEQ. ID. NO. 1) ##STR1##

Methods of treatment with novel antibiotic feglymycin

Novel polyene antibiotics, 3874 H1 to H6, processes for their preparation and use which are suitable for treating fungal diseases, trichomonad diseases, and for treating diseases associated with an increased steroid concentration.

Polyene antibiotics, 3874 H1 to H6, processes for their preparation and

This invention relates to the antibiotic feglymycin, as well as processes for its preparation and use. Feglymycin is represented by the structural formula (SEQ ID NO:1): ##STR1##

Antibiotic, feglymycin, processes for its preparation and its use

Compounds of the formula I, ##STR1## in which the symbols or substituents A, B, D, D*, E and E* have the meanings given in the specification, inhibit aspartyl proteases and are suitable for controlling viral diseases.

Phosphinic acid derivatives, their preparation and their use

Water-in-oil emulsions containing water-soluble alkyl glycosides

A fused ring system compound is disclosed that contains an epoxide group on one side of the fused rings and an enediyne macrocyclic ring on the other side of the fused rings. The compounds have DNA-cleaving, antimicrobial and tumor growth-inhibiting properties. Chimeric compounds having the fused ring system compound as an aglycone bonded to (i) a sugar moiety as the oligosaccharide portion or (ii) a monoclonal antibody or antibody combining site portion thereof that immunoreacts with target tumor cells are also disclosed. Compositions containing a compound or a chimer are disclosed, as are methods of preparing a compound.

Dynemicin analogs: syntheses, methods of preparation and use

Carbohydrate-containing polymers, their preparation and use

Intermediates useful in preparing the calicheamicin and esperamicin oligosaccharides, and particularly the sulfur- and O-substituted hydroxylamine-containing B ring of both oligosaccharides, are disclosed as are methods of making and using the same, including the preparation of chimeric antibiotics using the same.

Saccharide intermediates in the formation of the calicheamicin and

Dynemicin analogs: synthesis, methods of preparation and use

Growing community of inventors

Frankfurt am Main, Germany

Wilhelm Stahl